Kairos Pharma Wins Research and Development Excellence Award for Advanced Prostate Cancer Treatment.
ByAinvest
Wednesday, Dec 17, 2025 8:17 am ET1min read
KAPA--
Kairos Pharma has won the 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer for its work on ENV-105, a CD105-targeting monoclonal antibody designed to restore tumor sensitivity to hormone-based treatments in metastatic castration-resistant prostate cancer. The company earned this recognition for its positive interim safety and efficacy results in a Phase 2 clinical trial of ENV-105 in combination with apalutamide. Kairos Pharma aims to target the underlying biology that allows tumors to adapt and survive, with the potential to extend disease control for patients with limited options.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet